Home » PROTHERICS AND ASTRAZENECA ANNOUNCE LATE STAGE LICENSING AGREEMENT ON CYTOFAB FOR TREATMENT OF SEPSIS
PROTHERICS AND ASTRAZENECA ANNOUNCE LATE STAGE LICENSING AGREEMENT ON CYTOFAB FOR TREATMENT OF SEPSIS
Protherics, the biopharmaceutical company focused on critical care and oncology,
today announces an agreement with AstraZeneca for the global development and
commercialisation of Protherics' anti-sepsis product CytoFab. CytoFab is currently
being prepared for a single phase III registration study in severe sepsis in
line with guidance received at an end of phase II meeting with the US Food and
Drug Administration (FDA).
Market
Wire
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May